Loss of motor function linked to neurochemical biomarker: Study
MRI scans of the brains of people with amyotrophic lateral sclerosis (ALS) have identified a neurochemical called N-acetyl aspartate…
Articles by Steve Bryson, PhD
Health Canada resumes its review of add-on ALS therapy masitinib
Health Canada has resumed its review of AB Science’s application seeking approval of masitinib, an oral add-on therapy for…
Masitinib works best in moderate ALS, new trial analysis shows
Masitinib as an oral add-on therapy to Rilutek (riluzole) showed the greatest benefits in amyotrophic lateral sclerosis…
This immune protein plays key role in nerve damage, early study finds
An immune protein that is mostly produced in neurons was found to drive damage to mitochondria, which produce energy for…
EMA receives response for ongoing review of masitinib in treating ALS
AB Science has submitted its response to the European Medicines Agency (EMA), part of an ongoing review process…
COURAGE-ALS trial stopping after reldesemtiv fails to show benefits
Cytokinetics announced that it is stopping COURAGE-ALS, a Phase 3 trial investigating oral reldesemtiv in treating people with…
Anew’s ALS gene therapy shows promise in mice
Anew Medical‘s targeted gene therapy candidate, ANEW-202, eased multiple mechanisms associated with amyotrophic lateral sclerosis (ALS), leading to…
QurAlis secures $88M to advance ALS therapies
QurAlis has secured $88 million to advance the clinical development of QRL-101 and QRL-201, its lead candidates for amyotrophic…
Delayed diagnosis in ALS found in new AI analysis of patient records
Significant delays in the diagnosis of amyotrophic lateral sclerosis (ALS) were revealed by a new large-scale analysis of real-world…
Molecular ALS subtypes linked to age of disease onset, survival
Researchers have characterized three molecular subtypes of amyotrophic lateral sclerosis (ALS), each one associated with different clinical outcomes, including…